Last reviewed · How we verify

Asthma therapies — Competitive Intelligence Brief

Asthma therapies (Asthma therapies) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibodies (multiple agents with different targets). Area: Respiratory / Immunology.

marketed Monoclonal antibodies (multiple agents with different targets) IgE, IL-5, IL-4 receptor alpha (varies by specific agent) Respiratory / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Asthma therapies (Asthma therapies) — Genentech, Inc.. Asthma therapies from Genentech include multiple marketed drugs that work through different mechanisms to reduce airway inflammation and improve lung function in asthma patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Asthma therapies TARGET Asthma therapies Genentech, Inc. marketed Monoclonal antibodies (multiple agents with different targets) IgE, IL-5, IL-4 receptor alpha (varies by specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibodies (multiple agents with different targets) class)

  1. Genentech, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Asthma therapies — Competitive Intelligence Brief. https://druglandscape.com/ci/asthma-therapies. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: